scholarly journals Continuing aspirin desensitization therapy in a patient with aspirin exacerbated respiratory disease needing sinus surgery

2018 ◽  
Vol 1 (2) ◽  
Author(s):  
Nishioka GJ
Keyword(s):  
Respiratory Disease ◽  
Sinus Surgery ◽  
Aspirin Desensitization ◽  
Aspirin Exacerbated Respiratory Disease ◽  
Desensitization Therapy

Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease

2017 ◽  
Vol 8 (1) ◽  
pp. 49-53 ◽  
Author(s):  
Nithin D. Adappa ◽  
Viran J. Ranasinghe ◽  
Michal Trope ◽  
Steven G. Brooks ◽  
Jordan T. Glicksman ◽  
...  
Keyword(s):  
Respiratory Disease ◽  
Endoscopic Sinus Surgery ◽  
Sinus Surgery ◽  
Aspirin Desensitization ◽  
Aspirin Exacerbated Respiratory Disease

Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease

2018 ◽  
Vol 32 (4) ◽  
pp. 280-286 ◽  
Author(s):  
Kristen M. Walters ◽  
Jeremy D. Waldram ◽  
Katharine M. Woessner ◽  
Andrew A. White
Keyword(s):  
Respiratory Disease ◽  
Average Length ◽  
Airway Disease ◽  
Sinus Surgery ◽  
Response To Treatment ◽  
Aspirin Desensitization ◽  
Aspirin Exacerbated Respiratory Disease ◽  
Systemic Corticosteroids ◽  
Samter’S Triad

Background Aspirin-exacerbated respiratory disease (AERD), also known as Samter’s triad or aspirin (ASA)-intolerant asthma, affects 7% of asthmatics and has a higher prevalence in those with chronic rhinosinusitis and concomitant nasal polyposis. ASA desensitization with daily ASA therapy is a uniquely beneficial treatment for this disease entity and has been shown to have a significant impact on symptom scores, polyp disease, and need for systemic corticosteroids. However, no long-term studies have demonstrated whether or not ASA therapy remains safe and beneficial for these patients beyond 5–10 years. Objective This study was designed to determine the clinical course of AERD patients desensitized between 1995 and 2010. Methods A 20-question survey was distributed to patients who successfully completed ASA desensitization between January 1995 and April 2010. The questions were designed to assess ASA safety and longitudinal effects of ASA therapy in AERD. Results Of the 285 patients contacted, 92 (32%) completed the questionnaire. Average length of follow-up was 15 years. Of survey responders, 35 patients had discontinued ASA therapy. Although adverse reactions occurred, many also discontinued due to lack of efficacy or need for surgery. For those remaining on ASA (62%), significant improvement in sense of smell, asthma, sinus, and allergic rhinitis scores were noted ( P ≤ .001). The majority of ASA patients (68%) had a positive response to treatment and did not require further sinus surgery. However, ASA therapy did not delay the time to next sinus/polyp surgery ( P = .27) or reduce total number of sinus surgeries ( P = .56) compared to those who stopped treatment. Nearly 85% of AERD patients on ASA therapy found it to be helpful in improving airway disease and quality of life. Conclusion Aspirin desensitization followed by daily maintenance ASA therapy appears to be safe and effective even after 10+ years of continuous use.

Sign in / Sign up

Export Citation Format

Share Document